{"entity":{"id":"sc-101","kind":"drug","name":"SC-101","aka":[],"tldr":"SC-101 is an experimental peptide-drug conjugate from ConjuStar Biologics, in phase 2 trials for nectin-4-expressing advanced solid tumours, NECTIN4-amplified triple-negative breast cancer and NECTIN4-amplified HR-positive breast cancer.","summary":"SC-101 is a peptide-drug conjugate from ConjuStar Biologics. A peptide-drug conjugate that targets Nectin-4; the payload is not stated in the sources read. Its furthest stage is phase 2, for nectin-4-expressing advanced solid tumours, NECTIN4-amplified triple-negative breast cancer and NECTIN4-amplified HR-positive breast cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 in Nectin-4-expressing solid tumours recruiting (NCT06220838; dose-escalation results at ESMO 2025). Phase 2a in NECTIN4-amplified tumours recruiting (NCT07080619). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"ConjuStar Biologics: conjustar.com","url":"https://www.conjustar.com/"},{"label":"ConjuStar Biologics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07080619"},{"label":"ConjuStar Biologics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06220838"},{"label":"ClinicalTrials.gov: trials of SC-101","url":"https://clinicaltrials.gov/search?intr=SC-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":["nectin4"],"drugs":[],"companies":["conjustar-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06220838","nct07080619"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SC-101","modality":"Peptide-drug conjugate","mechanism":"A peptide-drug conjugate that targets Nectin-4; the payload is not stated in the sources read.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sc-101/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}],"company":[{"id":"conjustar-biologics","kind":"company","name":"ConjuStar Biologics","route":"/companies/conjustar-biologics/"}],"trial":[{"id":"nct07080619","kind":"trial","name":"SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers","route":"/trials/nct07080619/"},{"id":"nct06220838","kind":"trial","name":"Study SC-101 in Subjects With Advanced Malignancies","route":"/trials/nct06220838/"}]}}